Literature DB >> 33180658

CYP2C8 regulated by GAS5/miR-382-3p exerts anti-cancerous properties in liver cancer.

Kezhi Li1, Yonglun Chen2.   

Abstract

A cornucopia of literatures has characterized the involvement of a host of functional molecules in liver cancer. Herein, according to online datasets, we found that cytochrome P450 family 2 subfamily C member 8 (CYP2C8) was downregulated in liver cancer, and high CYP2C8 expression was associated with favorable overall survival. Lower levels of CYP2C8 were confirmed in liver cancer cells. CYP2C8 overexpression efficiently attenuated liver cancer cell proliferation and promoted apoptosis. We then discovered that miR-382-3p directly targeted CYP2C8 to inhibit its expression in liver cancer cells based on bioinformatic prediction and experimental confirmation. Moreover, a cytoplasmic long noncoding RNA (lncRNA), growth arrest-specific 5 (GAS5), sponged and down-regulated miR-382-3p, thus positively modulating CYP2C8 expression. Rescue assays indicated that GAS5 overexpression gave rise to decreased proliferation and increased apoptosis of liver cancer cells, while CYP2C8 knockdown counteracted GAS5-mediated anti-carcinogenic effects. In summary, our work offered a solid experimental foundation for understanding the functional role of CYP2C8 and the mechanism of GAS5/miR-382-3p/CYP2C8 axis in cell proliferation and apoptosis of liver cancer.

Entities:  

Keywords:  CYP2C8; GAS5; liver cancer; miR-382-3p

Year:  2020        PMID: 33180658     DOI: 10.1080/15384047.2020.1840886

Source DB:  PubMed          Journal:  Cancer Biol Ther        ISSN: 1538-4047            Impact factor:   4.742


  6 in total

Review 1.  Research Progress of Long Non-Coding RNA GAS5 in Malignant Tumors.

Authors:  Guohong Lin; Tianzhun Wu; Xing Gao; Ziqin He; Wenwei Nong
Journal:  Front Oncol       Date:  2022-06-28       Impact factor: 5.738

2.  Combination of Urine Exosomal mRNAs and lncRNAs as Novel Diagnostic Biomarkers for Bladder Cancer.

Authors:  Haiming Huang; Jialin Du; Bo Jin; Lu Pang; Nan Duan; Chenwei Huang; Jiayin Hou; Wei Yu; Han Hao; Haixia Li
Journal:  Front Oncol       Date:  2021-04-27       Impact factor: 6.244

3.  CYP2C8 Suppress Proliferation, Migration, Invasion and Sorafenib Resistance of Hepatocellular Carcinoma via PI3K/Akt/p27kip1 Axis.

Authors:  Xin Zhou; Tian-Man Li; Jian-Zhu Luo; Chen-Lu Lan; Zhong-Liu Wei; Tian-Hao Fu; Xi-Wen Liao; Guang-Zhi Zhu; Xin-Ping Ye; Tao Peng
Journal:  J Hepatocell Carcinoma       Date:  2021-11-03

4.  Development and validation of genomic and epigenomic signatures associated with tumor immune microenvironment in hepatoblastoma.

Authors:  Yanbing Zhang; Tian Zhang; Qiang Yin; Haiyan Luo
Journal:  BMC Cancer       Date:  2021-10-29       Impact factor: 4.430

5.  Identification and Quantification of Iron Metabolism Landscape on Therapy and Prognosis in Bladder Cancer.

Authors:  Xiaodong Song; Sheng Xin; Yucong Zhang; Jiaquan Mao; Chen Duan; Kai Cui; Liang Chen; Fan Li; Zheng Liu; Tao Wang; Jihong Liu; Xiaming Liu; Wen Song
Journal:  Front Cell Dev Biol       Date:  2022-02-21

6.  A Novel Four-Gene Signature as a Potential Prognostic Biomarker for Hepatocellular Carcinoma.

Authors:  Guangfeng Wang; Hao Zou; Yujie Feng; Wei Zhao; Kun Li; Kui Liu; Bingyuan Zhang; Chengzhan Zhu
Journal:  J Oncol       Date:  2021-12-14       Impact factor: 4.375

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.